Attributes | Values |
---|
rdf:type
| |
Description
| - Background In our study, we have concentrated on four aberrations in multiple myeloma (MM) malignant plasma cells: deletions of tumor suppressor genes RB (locus 13q14) and p53 (17q13), translocation involving IGH gene t(4;14), and actually focused amplification of CKS1B gene in 1q21 locus. All of these aberrations are known as negative prognostic factors in patients (pts) treated by conventional therapy or stem cell transplantation. Aims The aim of this study is to show if these selected aberrations act as negative prognostic factors also in patients treated by Velcade or by thalidomide, new drugs used in relapsed patients. Methods We have an increasing group of (recently 42) MM patients. Overall clinical characteristics of the patients at the start of treatment: Average age 63.7 years (SD = 9.4), 57 % (24) of men. 12 % (5/42 pts) were in stage IA, 26 % (11/42 pts) were in stage IIA, 60 % (25/42 pts) were in stage IIIA and 2 % (1 patient) was in stage IIIB.
- Background In our study, we have concentrated on four aberrations in multiple myeloma (MM) malignant plasma cells: deletions of tumor suppressor genes RB (locus 13q14) and p53 (17q13), translocation involving IGH gene t(4;14), and actually focused amplification of CKS1B gene in 1q21 locus. All of these aberrations are known as negative prognostic factors in patients (pts) treated by conventional therapy or stem cell transplantation. Aims The aim of this study is to show if these selected aberrations act as negative prognostic factors also in patients treated by Velcade or by thalidomide, new drugs used in relapsed patients. Methods We have an increasing group of (recently 42) MM patients. Overall clinical characteristics of the patients at the start of treatment: Average age 63.7 years (SD = 9.4), 57 % (24) of men. 12 % (5/42 pts) were in stage IA, 26 % (11/42 pts) were in stage IIA, 60 % (25/42 pts) were in stage IIIA and 2 % (1 patient) was in stage IIIB. (en)
|
Title
| - Do the %22new drugs%22 antagonize the impact of unfavourable cytogenetic markers in multiple myeloma?
- Do the %22new drugs%22 antagonize the impact of unfavourable cytogenetic markers in multiple myeloma? (en)
|
skos:prefLabel
| - Do the %22new drugs%22 antagonize the impact of unfavourable cytogenetic markers in multiple myeloma?
- Do the %22new drugs%22 antagonize the impact of unfavourable cytogenetic markers in multiple myeloma? (en)
|
skos:notation
| - RIV/00216224:14110/07:00022791!RIV10-MSM-14110___
|
http://linked.open...avai/riv/aktivita
| |
http://linked.open...avai/riv/aktivity
| |
http://linked.open...vai/riv/dodaniDat
| |
http://linked.open...aciTvurceVysledku
| - Pour, Luděk
- Kuglík, Petr
- Krejčí, Marta
- Hájek, Roman
- Adam, Zdeněk
- Němec, Pavel
- Filková, Hana
- Oltová, Alexandra
- Křivanová, Andrea
- Grešliková, Henrieta
- Zaoralová, Romana
- Smejkalová, Jana
|
http://linked.open.../riv/druhVysledku
| |
http://linked.open...iv/duvernostUdaju
| |
http://linked.open...titaPredkladatele
| |
http://linked.open...dnocenehoVysledku
| |
http://linked.open...ai/riv/idVysledku
| - RIV/00216224:14110/07:00022791
|
http://linked.open...riv/jazykVysledku
| |
http://linked.open.../riv/klicovaSlova
| - multiple myeloma; cIg FISH; velcade; thalidomide (en)
|
http://linked.open.../riv/klicoveSlovo
| |
http://linked.open...ontrolniKodProRIV
| |
http://linked.open...v/mistoKonaniAkce
| |
http://linked.open...i/riv/mistoVydani
| |
http://linked.open...i/riv/nazevZdroje
| |
http://linked.open...in/vavai/riv/obor
| |
http://linked.open...ichTvurcuVysledku
| |
http://linked.open...cetTvurcuVysledku
| |
http://linked.open...vavai/riv/projekt
| |
http://linked.open...UplatneniVysledku
| |
http://linked.open...iv/tvurceVysledku
| - Adam, Zdeněk
- Hájek, Roman
- Krejčí, Marta
- Kuglík, Petr
- Pour, Luděk
- Němec, Pavel
- Filková, Hana
- Oltová, Alexandra
- Grešliková, Henrieta
- Křivanová, Andrea
- Zaoralová, Romana
- Smejkalová, Jana
|
http://linked.open...vavai/riv/typAkce
| |
http://linked.open.../riv/zahajeniAkce
| |
issn
| |
number of pages
| |
http://purl.org/ne...btex#hasPublisher
| |
http://localhost/t...ganizacniJednotka
| |
is http://linked.open...avai/riv/vysledek
of | |